Rare Disease Trial, Recruiting (NCT03740503)

Rare Disease Trial, Recruiting NCT03740503 Sponsor: University Health Network, Toronto Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT03740503 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You had an unusually good response to a cancer treatment (for example, your cancer went away completely, partly, or stayed stable for at least 6 months).
You had an unexpectedly poor response to a treatment that was expected to work well for you (for example, your tumor grew dramatically or you became very unwell despite treatment).
Your doctor has identified your response to treatment as being exceptionally unusual in either direction.
There is enough stored tumor tissue available from a previous biopsy or surgery to be tested.
Patients who have passed away may also be included (up to 30 per year) if their stored tumor tissue is held within the UHN Laboratory Medicine Program and permission to access it has been granted, OR if their tissue is stored in the UHN Biospecimen Sciences Program for research purposes.

Who may not be able to join:

There are no official exclusion criteria listed for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Cescon, MD, Princess Margaret Cancer Centre

Phone: 416-946-4501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03740503

Sponsor: University Health Network, Toronto

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: 416-946-4501

More information: https://clinicaltrials.gov/study/NCT03740503

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You had an unusually good response to a cancer treatment (for example, your cancer went away completely, partly, or stayed stable for at least 6 months).
You had an unexpectedly poor response to a treatment that was expected to work well for you (for example, your tumor grew dramatically or you became very unwell despite treatment).
Your doctor has identified your response to treatment as being exceptionally unusual in either direction.
There is enough stored tumor tissue available from a previous biopsy or surgery to be tested.
Patients who have passed away may also be included (up to 30 per year) if their stored tumor tissue is held within the UHN Laboratory Medicine Program and permission to access it has been granted, OR if their tissue is stored in the UHN Biospecimen Sciences Program for research purposes.

Who may not be able to join:

There are no official exclusion criteria listed for this trial.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Health Network, Toronto

Registry

ClinicalTrials.gov

Start date

1 November 2013

Est. completion

1 November 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Genomic Characterization of Tumor Samples

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov